This is a routine executive appointment with no immediate trading implications. Monitor future filings for APITOX regulatory milestones or clinical trial updates that could move the stock.
Price Chart
Executive Summary
Apimeds Pharmaceuticals appointed Dr. Christopher Kim as Chief Scientific Officer, effective August 5, 2026, to lead the APITOX program's scientific, clinical, and regulatory development. This is a routine organizational change with no financial terms or material business developments disclosed.
Key Facts
- Dr. Christopher Kim appointed as Chief Scientific Officer effective August 5, 2026
- Dr. Kim will lead the APITOX program including R&D, clinical strategy, regulatory engagement, and commercialization efforts
- No compensation, equity awards, or other financial terms disclosed in the filing
Financial Impact
Not specified
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-086244 |
| Document: 0001213900-26-086244-index-headers.html | 0001213900-26-086244 |
| Document: 0001213900-26-086244-index.html | 0001213900-26-086244 |
| Document: 0001213900-26-086244.txt | 0001213900-26-086244 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | Press Release | $4.62 | awaiting T+60 | awaiting T+60 | $3.05 (−33.98%) |
Oct 13, 2026 14d ago | 8-K | $4.62 | awaiting T+60 | awaiting T+60 | $3.05 (−33.98%) |
Oct 1, 2026 26d ago | 8-K | $4.10 | awaiting T+60 | awaiting T+60 | $3.05 (−25.61%) |
Sep 22, 2026 5w ago | 8-K | $2.29 | awaiting T+60 | awaiting T+60 | $3.05 (+33.19%) |
Aug 21, 2026 9w ago | 8-K | $4.75 | awaiting T+60 | awaiting T+60 | $3.05 (−35.79%) |
Aug 6, 2026 11w ago | 8-K | $4.23 | awaiting T+60 | awaiting T+60 | $3.05 (−27.90%) |
May 5, 2026 25w ago | 8-K | $30.00 $4.92 | ▼ −83.60% | ▼ −86.34% | $3.05 (−89.83%) |
May 4, 2026 25w ago | 8-K | $1.88 $5.75 | ▼ −205.85% | ▼ −203.99% | $3.05 (−62.23%) |
Apr 16, 2026 27w ago | 8-K | $1.88 $0.7324 | ▲ +61.04% | ▲ +67.19% | $3.05 (−62.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers